Curasight (CURAS) Q2 2025 earnings summary

Executive summary

• Advanced uPAR-targeted theranostic solutions, focusing on prostate cancer and glioblastoma, with key milestones in both programs.

• Strategic partnership with Curium for global development and commercialization of uTRACE® in prostate cancer, with first milestone payment received.

• Multiple ongoing and planned clinical trials, including phase 1 for uTREAT® in glioblastoma and expanded phase 2 uTRACE® trial in prostate cancer.

• Successful rights issue raised DKK 47 million and DKK 18 million in loans, strengthening the financial base.

• EMA approved clinical trial application for phase 1 uTREAT® in glioblastoma; first patient dosing expected H2 2025.

Financial highlights

• Q1–Q2 2025 gross loss: kDKK -22,399 (vs. kDKK -16,386 year-over-year); Q2 2025 gross loss: kDKK -17,700 (Q2 2024: kDKK -9,001).

• Operating loss: kDKK -25,220 (vs. kDKK -20,345 year-over-year); Q2 2025 operating loss: kDKK -19,011 (Q2 2024: kDKK -10,969).

• Loss for the period: kDKK -24,408 (vs. kDKK -18,729 year-over-year); Q2 2025 loss: kDKK -19,204 (Q2 2024: kDKK -10,737).

• Cash in hand as of June 30, 2025: kDKK 29,449 (vs. kDKK 8,384 year-over-year).

• Equity ratio improved to 67.6% (43.9% in 2024); EPS for H1 2025: DKK -0.54 (H1 2024: DKK -0.94).

Outlook and guidance

• EMA approval for phase 1 trial of uTREAT® in glioblastoma, with first patient dosing planned for H2 2025.

• Preliminary efficacy data for uTREAT® in brain cancer expected by end of Q4 2025.

• Topline results for uTRACE® in prostate cancer anticipated H1 2026, with recruitment to complete in H1 2026.

• Plans to initiate a phase II basket trial in 2026 for multiple cancer indications.